title: Telavancin.
abstract: Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous telavancin 10 mg/kg once daily (administered as a 1-hour infusion) was effective in the treatment of adult patients with cSSSIs, including those with infections caused by MRSA, as shown by clinical cure rates in clinically evaluable, all-treated and microbiologically evaluable populations at the test-of-cure (TOC) visit. Telavancin 10 mg/kg once daily was noninferior to intravenous vancomycin 1 g every 12 hours, with clinical cure rates of 88% versus 87% at the TOC visit in pooled data from the clinically evaluable population (n = 1489) of two phase III trials. Pooled clinical cure rates in telavancin recipients at the TOC visit were also not significantly different from those in vancomycin recipients in the all-treated or microbiologically evaluable populations, including microbiologically evaluable subgroups with baseline infections caused by MRSA, meticillin-susceptible S. aureus or other Gram-positive pathogens. Telavancin was generally well tolerated in patients with cSSSIs, with most adverse events being of mild or moderate severity.
authors: Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
authors: Katherine A
authors: KA
authors: Lyseng-Williamson
authors: Stephanie K A
authors: SK
authors: Blick
mesh_terms: D000328:Adult; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D003428:Cross Infection; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004347:Drug Interactions; D024901:Drug Resistance, Multiple, Bacterial / Q000502:physiology; D006094:Gram-Positive Bacteria; D006801:Humans; D000077427:Lipoglycopeptides; D008712:Methicillin / Q000627:therapeutic use*; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000008:administration & dosage; D012874:Skin Diseases, Infectious; D013203:Staphylococcal Infections / Q000188:drug therapy*; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D014640:Vancomycin; D008712:Methicillin; D010068:Oxacillin; C487637:telavancin